Genfit SA - ESG Rating & Company Profile powered by AI
This report of Genfit SA was prepared by All Street Sevva using advanced Cognitive Robots. If you work at Genfit SA and you wish to licence your Sustainability rating, please get in touch. Scroll down to the end of the page for potential risks for Genfit SA based on industry, location and marketcap.
Genfit SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 5.3, social score of 4.8 and governance score of 8.0.
6.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
| 483 | aTyr Pharma Inc | 6.1 | High |
| 498 | Genfit SA | 6.0 | High |
| 498 | Cann Group Ltd | 6.0 | High |
| 498 | Biosynex SA | 6.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Genfit SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Genfit SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Genfit SA report the average age of the workforce?
Sign up for free to unlockDoes Genfit SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Genfit SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Genfit SA disclose cybersecurity risks?
Sign up for free to unlockDoes Genfit SA offer flexible work?
Sign up for free to unlockDoes Genfit SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Genfit SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Genfit SA conduct supply chain audits?
Sign up for free to unlockDoes Genfit SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Genfit SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Genfit SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Genfit SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Genfit SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Genfit SA disclose water use targets?
Sign up for free to unlockDoes Genfit SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Genfit SA have a product recall in the last two years?
Sign up for free to unlockDoes Genfit SA disclose incidents of discrimination?
Sign up for free to unlockDoes Genfit SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Genfit SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Genfit SA disclose parental leave metrics?
Sign up for free to unlockDoes Genfit SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Genfit SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Genfit SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Genfit SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Genfit SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Genfit SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Genfit SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Genfit SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Genfit SA disclose its waste policy?
Sign up for free to unlockDoes Genfit SA report according to TCFD requirements?
Sign up for free to unlockDoes Genfit SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Genfit SA disclose energy use targets?
Sign up for free to unlockDoes Genfit SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Genfit SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Genfit SA
These potential risks are based on the size, segment and geographies of the company.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.